Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991911 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT02991911 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 33 participants.
The verdict
NCT02991911, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD \[in the absence of establishing the MTD\]) for single agent MEDI3726 in subjects with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
Interventions
- BIOLOGICAL MEDI3726 Post-Chemo
- BIOLOGICAL MEDI3726 Pre-Chemo
- BIOLOGICAL MEDI3726 & Enzalutamide Combo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2019-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02991911
The ClinicalTrials.gov registry entry for NCT02991911 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MEDI3726 Post-Chemo is the first listed.
NCT02991911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02991911 about?
NCT02991911 is a clinical study titled "A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer". The purpose of this study is to assess the safety and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD \[in the absence of establishing the MTD\]) for single agent MEDI3726 in subjects with mCRPC who have rec...
What is the current status of trial NCT02991911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2017-01-06. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT02991911?
The interventions under investigation include: MEDI3726 Post-Chemo (BIOLOGICAL), MEDI3726 Pre-Chemo (BIOLOGICAL), MEDI3726 & Enzalutamide Combo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02991911?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.